Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Nov 5, 2021
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called time-restricted eating, which is a way of eating that limits the hours in which you can consume food each day. Researchers are exploring whether this approach can help people who are obese lose weight and lower their risk of developing colorectal cancer, a type of cancer that affects the colon and rectum. They believe that helping individuals manage their weight could have significant health benefits.
To be eligible for the trial, participants need to be between 45 and 70 years old and have a body mass index (BMI) between 30 and 49.99, which indicates obesity. They must also be up to date with screenings for colorectal cancer. However, individuals with certain health conditions, recent cancer treatments, or those who are pregnant or trying to become pregnant cannot participate. If selected, participants will learn more about time-restricted eating and how to keep track of their food intake. This trial is a chance to contribute to important research that could improve health outcomes for people struggling with obesity and colorectal cancer risk.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 45-70 years old,
- • 2. BMI 30-49.99 kg/m2
- • 3. Are up to date with CRC screening.
- Exclusion Criteria:
- • 1. Have a history of renal disease, autoimmune disorders, immunodeficiency, malabsorptive disorder, significant gastrointestinal and hepatic disease, surgical change in gastrointestinal anatomy, severe ischemic heart disease, severe pulmonary disease, severe mental health disorder, eating disorder, or bariatric surgery;
- • 2. Abuse alcohol (\> 50 grams/day), illicit drugs (other than self-reported marijuana use), or use combustible tobacco;
- • 3. Have controlled type 2 diabetes or undiagnosed uncontrolled diabetes based on hemoglobin A1c (HbA1c) \> 9.0%;
- • 4. Have a history of cancer treatment within the past 12 months, CRC, genetic predisposition to CRC (e.g., Lynch syndrome);
- • 5. Have a baseline body weight \> 450 lbs (weight limitation of the DXA);
- • 6. Are on a weight loss diet or actively involved in a formal weight loss program (e.g., Weight Watchers);
- • 7. Are not weight stable for 3 months prior to the study (weight gain or loss \> 4 kg);
- • 8. Are unable to keep a food diary for 7 consecutive days during screening;
- • 9. Are night shift workers;
- • 10. Are pregnant or trying to get pregnant;
- • 11. Are taking drugs that influence study outcomes (weight loss medications);
- • 12. Are non-English speaking
- • 13. Are taking anticoagulant medications or medications with endoscopic risk
- • 14. Are taking antivirals or immunosuppressant medications
- • 15. Don't have regular access to an email address and computer/smartphone/tablet
- • 16. Are currently following a diet that requires fasting on a weekly basis
- • 17. Currently eat for less than 10 hours of the day (determined by asking participants what time they start and stop eating on a usual day)
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Lisa Tussing-Humphreys, PhD, MS, RD
Principal Investigator
University of Illinois at Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials